Experimental obesity drug reduces sleep apnea symptoms in clinical trials
Retatrutide significantly reduced breathing interruptions and improved cardiovascular risk factors in adults with moderate-to-severe obstructive sleep apnea.

An experimental obesity drug significantly reduced breathing interruptions and other symptoms of obstructive sleep disorder in two clinical trials, according to research published in The New England Journal of Medicine. The drug, retatrutide from Eli Lilly, reduced the apnea-hypopnea index, which counts breathing interruptions per hour of sleep, in adults who were overweight or obese.
The two phase 3 randomized trials included 691 adults with a BMI of at least 27 and moderate-to-severe sleep apnea. Participants received once-weekly injections of retatrutide at doses of 4, 9 or 12 milligrams, or a placebo, and were followed for 80 weeks. The trials included 243 participants without type 2 diabetes and 448 with the condition.
Participants receiving retatrutide lost between 12% and nearly 20% of their body weight and experienced significantly fewer breathing interruptions than those who received a placebo. About 68% of participants experienced more than a 50% improvement in obstructive sleep apnea symptoms, regardless of whether they had type 2 diabetes. The condition completely resolved in about 25% of participants without diabetes and 15% of those with type 2 diabetes.
Cardiologist Dr. Virend Somers, a professor of medicine at Mayo Clinic, said the drug improved several cardiovascular risk factors, including systolic blood pressure, LDL cholesterol, systemic inflammation and neck circumference. Among those with type 2 diabetes, 40% progressed to prediabetes and another 40% no longer met the criteria for diabetes.
The drug has not been approved by the FDA, which has warned that unauthorized versions of retatrutide have been illegally marketed and sold online for weight loss. Researchers noted that further studies are needed to determine how the drug may affect long-term cardiovascular outcomes and its long-term safety and effectiveness for sleep apnea.
Key facts
- Retatrutide participants lost between 12% and nearly 20% of their body weight.
- About 68% of participants saw more than a 50% improvement in sleep apnea symptoms.
- The drug is currently being evaluated in phase 3 TRIUMPH trials and is not FDA approved.
Three perspectives
Neutral
Retatrutide is an investigational weight-loss drug being evaluated in phase 3 trials for obesity and related metabolic conditions.
Positive
The drug led to significant reductions in breathing interruptions and improved several cardiovascular risk factors.
Negative
The drug has not been approved by the FDA, and unauthorized versions have been illegally sold online.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.